Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status
Open Access
- 18 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-17
- https://doi.org/10.1186/s12885-020-06908-z
Abstract
Prostate cancer (PC) can display very heterogeneous phenotypes ranging from indolent asymptomatic to aggressive lethal forms. Understanding how these PC subtypes vary in their striving for energy and anabolic molecules is of fundamental importance for developing more effective therapies and diagnostics. Here, we carried out an extensive analysis of prostate tissue samples to reveal metabolic alterations during PC development and disease progression and furthermore between TMPRSS2-ERG rearrangement-positive and -negative PC subclasses. Comprehensive metabolomics analysis of prostate tissue samples was performed by non-destructive high-resolution magic angle spinning nuclear magnetic resonance (1H HR MAS NMR). Subsequently, samples underwent moderate extraction, leaving tissue morphology intact for histopathological characterization. Metabolites in tissue extracts were identified by 1H/31P NMR and liquid chromatography-mass spectrometry (LC-MS). These metabolomics profiles were analyzed by chemometric tools and the outcome was further validated using proteomic data from a separate sample cohort. The obtained metabolite patterns significantly differed between PC and benign tissue and between samples with high and low Gleason score (GS). Five key metabolites (phosphocholine, glutamate, hypoxanthine, arginine and α-glucose) were identified, who were sufficient to differentiate between cancer and benign tissue and between high to low GS. In ERG-positive PC, the analysis revealed several acylcarnitines among the increased metabolites together with decreased levels of proteins involved in β-oxidation; indicating decreased acyl-CoAs oxidation in ERG-positive tumors. The ERG-positive group also showed increased levels of metabolites and proteins involved in purine catabolism; a potential sign of increased DNA damage and oxidative stress. Our comprehensive metabolomic analysis strongly indicates that ERG-positive PC and ERG-negative PC should be considered as different subtypes of PC; a fact requiring different, sub-type specific treatment strategies for affected patients.Keywords
Funding Information
- Vetenskapsrådet (2016-06963)
- Cancerfonden (170211)
- Stiftelsen för Strategisk Forskning (RB13-0119)
This publication has 61 references indexed in Scilit:
- Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer AggressivenessPLOS ONE, 2013
- Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductaseFEBS Open Bio, 2012
- Application of metabolomics to prostate cancerUrologic Oncology, 2011
- Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environmentNMR in Biomedicine, 2011
- Urinary acylcarnitines are altered in human kidney cancerInternational Journal of Cancer, 2011
- Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohortLaboratory Investigation, 2010
- Oxidative stress in prostate cancerCancer Letters, 2009
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature, 2009
- Peroxisomal branched chain fatty acid ?-oxidation pathway is upregulated in prostate cancerThe Prostate, 2004